Clinical Trials
4 trialsNCT06761677 2026-02-05
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
SymBio Pharmaceuticals
Phase 1/2 Suspended
NCT02580539 2025-05-14
EBV-TCL-01
Maisonneuve-Rosemont Hospital
Phase 1/2 Completed
NCT01805037 2021-09-01
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Northwestern University
Phase 1/2 Terminated
NCT02229981 2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2 Withdrawn